Loading
A phase 3 trial testing Atebimetinib in pancreatic ductal adenocarcinoma, now recruiting.
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07562152, led by Immuneering, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301). Planned enrolment is 510 participants (estimated). The study started in 2026-06-05 and primary completion is expected in 2028-06. No results have been posted on ClinicalTrials.gov.